Pediatric Infection and Vaccine

  • 제19권1호
  • /
  • Pages.1-11
  • /
  • 2012
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

면역저하환자에서 인플루엔자백신의 면역원성 평가

Assessment of Influenza Vaccine Immunogenicity in Immunocompromized Host During 2009 Influenza Season: A Single Institution Experience

  • 김동환 (한국원자력의학원 소아청소년과) ;
  • 송봉섭 (한국원자력의학원 소아청소년과) ;
  • 이준아 (한국원자력의학원 소아청소년과) ;
  • 김동호 (한국원자력의학원 소아청소년과)
  • Kim, Dong Hwan (Department of Pediatrics, Korea Cancer Center Hospital) ;
  • Song, Bong Sup (Department of Pediatrics, Korea Cancer Center Hospital) ;
  • Lee, Jun Ah (Department of Pediatrics, Korea Cancer Center Hospital) ;
  • Kim, Dong Ho (Department of Pediatrics, Korea Cancer Center Hospital)
  • 투고 : 2011.09.15
  • 심사 : 2011.10.28
  • 발행 : 2012.04.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 인플루엔자는 소아암 환자에게 이환율과 사망률이 높은 질환이나 소아암 환자에 대한 예방 접종률은 낮은 상태이다. 본 연구에서는 소아암 환자를 대상으로 인플루엔자 예방접종의 면역원성과 부작용에 대한 평가를 시행하였다. 방 법 : 2009년 10월부터 12월까지 원자력의학원에서 인플루엔자 예방접종(SK influenza IX vaccine$^{(R)}$)을 받은 25명의 소아암 환자를 대상으로 연구를 시행했다. 예방접종일과 접종 후 30일 뒤 2회에 걸쳐 채혈하였고 혈구응집억제 항체가를 측정하였다. 백신의 면역원성은 접종 전과 접종 후 30일의 혈구응집억제 항체가 1:40 이상인 피험자 비율, 접종 후 30일의 항체 양전율, 접종 전과 접종 후 30일 사이의 GMT 증가 배수로 평가하였다. 결 과 : 본 연구대상자 중에서 심각한 예방접종관련 부작용을 경험한 대상자는 없었다. 접종 후 혈구응집억제 항체가 1:40 이상을 보인 피험자의 비율은 H1N1 항원에 대해 68%, H3N2 항원에 대해 40%, B 항원에 대해 36%였다. 항체양전율은 H1N1 항원에 대해 12%, H3N2 항원에 대해 16%, B 항원에 대해 20%였다. GMT 증가 배수는 H1N1 항원에 대해 0.9, H3N2 항원에 대해 1.2, B 항원에 대해 1.8이었다. 결 론 : 본 연구의 대상자들은 인플루엔자 백신에 대해 제한적인 면역반응을 보였으나 일부 대상자들에게서 항체 양전이 나타났고 심각한 예방접종관련 부작용이 없었던 점을 고려할 때 소아암환자를 대상으로 매년 정기적인 인플루엔자 예방접종이 추천된다.

Purpose : Although influenza is regarded as one of the major causes of morbidity and mortality in children with cancer, the actual vaccine coverage remains poor. We conducted evaluation of immunogenicity and safety of influenza vaccine in children with cancer. Methods : In this study, 25 children with cancer who received influenza vaccine (SK influenza IX vaccine$^{(R)}$) at the Korea Cancer Center Hospital between October and December 2009 were analyzed. Blood samples of patients were collected twice (at the beginning of this study and at 30th day after vaccination) and their antibody titers were measured using the hemagglutination-inhibition (HI) assay. Immunogenicity of the influenza vaccine was assessed by seroprotection rate on days 0 and 30, seroconversion rate on day 30, and mean fold increase (MFI) of geometric mean titer (GMT) of HI between days 0 and 30. Results : Any of the subjects in our study did not experienced serious adverse events after influenza vaccination. Seroprotection rates were 68% for H1N1, 40% for H3N2, and 36% for B. Seroconversion rates were 12% for H1N1, 16% for H3N2, and 20% for B. MFIs were 0.9 for H1N1, 1.2 for H3N2, and 1.8 for B. Conclusion : In the study, we found a limited protective immune response to influenza vaccine, among subjects with cancer. However, some subjects showed seroconversion, and there were no severe adverse events among all subjects, supporting the recommendation of annual influenza vaccination in children with cancer.

키워드

참고문헌

  1. Lapinsky SE. H1N1 novel influenza A in pregnant and immunocompromised patients. Crit Care Med 2010;38:e52-7. https://doi.org/10.1097/CCM.0b013e3181c85d5f
  2. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of influenza: recommendations for influenza immunization of children, 2008-2009. Pediatrics 2008;122:1135-41. https://doi.org/10.1542/peds.2008-2449
  3. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57:1-60.
  4. Principi N, Esposito S. Are we ready for universal influenza vaccination in paediatrics? Lancet Infect Dis 2004;4:75-83. https://doi.org/10.1016/S1473-3099(04)00926-0
  5. Esposito S, Marchisio P, Principi N. The global state of influenza in children. Pediatr Infect Dis J 2008;27:S149-53. https://doi.org/10.1097/INF.0b013e31818a542b
  6. Cho BH, Kolasa MS, Messonnier ML. Influenza vaccination coverage rate among high-risk children during the 2002-2003 influenza season. Am J Infect Control 2008;36:582-7. https://doi.org/10.1016/j.ajic.2007.09.013
  7. Nakamura MM, Lee GM. Influenza vaccination in adolescents with high-risk conditions. Pediatrics 2008;122:920-8. https://doi.org/10.1542/peds.2007-3032
  8. Esposito S, Marchisio P, Droghetti R, Lambertini L, Faelli N, Bosis S, et al. Influenza vaccination coverage among children with high-risk medical conditions. Vaccine 2006;24:5251-5. https://doi.org/10.1016/j.vaccine.2006.03.059
  9. Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008;19:1658.
  10. Matsuzaki A, Suminoe A, Koga Y, Kinukawa N, Kusuhara K, Hara T. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005;45:831-7. https://doi.org/10.1002/pbc.20470
  11. Shahgholi E, Ehsani MA, Salamati P, Maysamie A, Sotoudeh K, Mokhtariazad T. Immunogenicity of trivalent influenza vaccine in children with acute lymphoblastic leukemia during maintenance therapy. Pediatr Blood Cancer 2010;54:716-20. https://doi.org/10.1002/pbc.22421
  12. Opstelten W, Rimmelzwaan GF, van Essen GA, Bijlsma JW. Influenza vaccination of immunocompromised patients: safe and effective. Ned Tijdschr Geneeskd 2009;153:A902.
  13. Korea Centers for Disease Control and Prevention. Korean Influenza Surveillance Report, 2007-2008. 2011.
  14. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43:25-30. https://doi.org/10.1002/1097-0142(197901)43:1<25::AID-CNCR2820430103>3.0.CO;2-Q
  15. Chisholm JC, Devine T, Charlett A, Pinkerton CR, Zambon M. Response to influenza immunisation during treatment for cancer. Arch Dis Child 2001;84:496-500. https://doi.org/10.1136/adc.84.6.496
  16. Gross PA, Lee H, Wolff JA, Hall CB, Minnefore AB, Lazicki ME. Influenza immunization in immunosuppressed children. J Pediatr 1978;92:30-5. https://doi.org/10.1016/S0022-3476(78)80065-1
  17. Ljungman P, Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008;42:637-41. https://doi.org/10.1038/bmt.2008.264
  18. Bektas O, Karadeniz C, Oguz A, Berberoglu S, Yilmaz N, Citak C. Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors. Pediatr Blood Cancer 2007;49:914-7. https://doi.org/10.1002/pbc.21106